AI Insight
This randomized controlled trial conducted in India compared an 8-week versus 12-week course of sofosbuvir-velpatasvir treatment in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis. The study demonstrated non-inferiority of the shorter 8-week regimen compared to the standard 12-week treatment in achieving sustained virologic response. The findings suggest that treatment duration can be safely reduced in this specific patient population without compromising efficacy.
Why it matters
Shortening the treatment duration from 12 to 8 weeks could reduce healthcare costs, improve patient adherence, and decrease medication-related side effects while maintaining comparable cure rates. This is particularly significant for countries like India with high hepatitis C burden, as it could expand access to treatment and support global HCV elimination goals.
Understand the Science
An 8-week regimen of sofosbuvir–velpatasvir was similar in efficacy to the standard 12-week treatment in individuals with chronic HCV infection without cirrhosis. This finding supports shortening the duration of treatment in such patients.